Incyte (INCY) Shares Outstanding (Weighted Average) (2010 - 2026)
Incyte (INCY) reported Shares Outstanding (Weighted Average) of $199.3 million for Q1 2026, up 2.91% on a YoY basis from $193.7 million in Q1 2025, and up 2.12% quarter-over-quarter from $195.2 million in Q4 2025.
Incyte (INCY) Shares Outstanding (Weighted Average) (2010 - 2026) Analysis & Trends
Incyte has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $199.3 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 2.91% year-over-year to $199.3 million; the trailing twelve-month figure through Mar 2026 stood at $199.3 million (up 2.91% YoY), and the FY2025 full-year result was $195.2 million, down 5.75% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $199.3 million, up from $195.2 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $224.5 million in Q1 2024, with the low at $193.7 million in Q1 2025.
- Historically, Shares Outstanding (Weighted Average) has averaged $212.9 million across 5 years, with a median of $221.3 million in 2022.
- Annual changes were most pronounced in 2025 — Shares Outstanding (Weighted Average) decreased 13.71% — and 2026, when it climbed 2.91%.
- Incyte's Shares Outstanding (Weighted Average) stood at $222.0 million in 2022, then increased by 0.73% to $223.6 million in 2023, then dropped by 7.39% to $207.1 million in 2024, then decreased by 5.75% to $195.2 million in 2025, then grew by 2.12% to $199.3 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $199.3 million (Q1 2026), $195.2 million (Q4 2025), and $195.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 199.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 199.34 Mn |
| Dec 31, 2025 | 195.20 Mn |
| Sep 30, 2025 | 195.67 Mn |
| Jun 30, 2025 | 194.00 Mn |
| Mar 31, 2025 | 193.71 Mn |
| Dec 31, 2024 | 207.11 Mn |
| Sep 30, 2024 | 211.76 Mn |
| Jun 30, 2024 | 218.18 Mn |
| Mar 31, 2024 | 224.48 Mn |
| Dec 31, 2023 | 223.63 Mn |
| Sep 30, 2023 | 223.43 Mn |
| Jun 30, 2023 | 223.10 Mn |
| Mar 31, 2023 | 222.96 Mn |
| Dec 31, 2022 | 222.00 Mn |
| Sep 30, 2022 | 221.80 Mn |
| Jun 30, 2022 | 221.49 Mn |
| Mar 31, 2022 | 221.33 Mn |
| Dec 31, 2021 | 220.43 Mn |
| Sep 30, 2021 | 220.85 Mn |
| Jun 30, 2021 | 219.94 Mn |